KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fulgent Genetics (FLGT) Operating Expenses (2016 - 2025)

Fulgent Genetics' Operating Expenses history spans 11 years, with the latest figure at $68.8 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 43.42% year-over-year to $68.8 million; the TTM value through Dec 2025 reached $222.0 million, up 22.55%, while the annual FY2025 figure was $222.0 million, 22.55% up from the prior year.
  • Operating Expenses for Q4 2025 was $68.8 million at Fulgent Genetics, up from $50.9 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $176.4 million in Q4 2023 and bottomed at $18.4 million in Q1 2021.
  • The 5-year median for Operating Expenses is $44.6 million (2024), against an average of $49.6 million.
  • The largest annual shift saw Operating Expenses soared 255.98% in 2023 before it tumbled 72.79% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $38.7 million in 2021, then increased by 28.08% to $49.5 million in 2022, then skyrocketed by 255.98% to $176.4 million in 2023, then plummeted by 72.79% to $48.0 million in 2024, then soared by 43.42% to $68.8 million in 2025.
  • Per Business Quant, the three most recent readings for FLGT's Operating Expenses are $68.8 million (Q4 2025), $50.9 million (Q3 2025), and $54.1 million (Q2 2025).